News & Events

Castle Biosciences Announces Data Presentations at the Association for Molecular Pathology 2016 Annual Meeting with Gene Expression Profile Tests for Uveal and Cutaneous Melanoma

Friendswood, TX – November 14, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from studies evaluating clinical experience with gene expression profile (GEP) tests DecisionDx®-Melanoma and DecisionDx®-UM. In the studies, both GEP tests demonstrated a high technical success rate with robust, reproducible and reliable performance. The data were presented in poster sessions at the Association for Molecular Pathology (AMP) 2016 Annual Meeting, which was held more »

Castle Biosciences Announces Data Presentation at the Society for Melanoma Research 2016 Congress Demonstrating Clinical Impact of DecisionDx-Melanoma Test Results on Patient Management

Friendswood, TX – November 10, 2016 – Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced results from a study evaluating the clinical impact of its gene expression profile (GEP) test DecisionDx®-Melanoma on patient management decisions. The test uses tumor biology to provide an individual risk of recurrence in cutaneous (skin) melanoma patients. The data were presented in a poster session at the Society for Melanoma Research 2016 Congress, more »

Gene Expression Profiling Can Influence Melanoma Management

Clinical Oncology News | October 5, 2016 | Ajai Raj | A gene expression profiling test that classifies cutaneous melanoma (CM) patients into high- or low-risk categories for metastasis has been found to influence clinical management of CM patients, according to a team of investigators at multiple institutions in the United States. Publishing in Current Medical Research and Opinion (2016;32[9]:1599-1604, PMID: 27210115), the investigators wrote that “the vast majority” of clinical changes implemented after the receipt of results from DecisionDx-Melanoma (Castle Biosciences), a 31-gene expression profiling more »

Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting

Boston, MA—July 28, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx®-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical validation studies and further support the test’s a bility to identify patients’ risk of melanoma recurrence in the five years more »

Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion

Friendswood, TX—July 11, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a prospectively designed, multicenter, decision impact study of its gene expression profile (GEP) test for cutaneous melanoma. The DecisionDx®-Melanoma GEP test accurately predicts etastatic risk independent of current diagnostic modalities including AJCC staging. The paper, “Clinical impact of a 31-gene expression profile test for cutaneous melanoma in 156 prospectively and consecutively tested patients,” was more »

« Newer EntriesOlder Entries »
Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation